• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

Vida Health reports positive data for virtual diabetes program in low-income populations

June 27, 2023 By Sean Whooley

A person uses the Vida Health digital diabetes management program on their smartphone.
[Image courtesy of Vida Health]
Vida Health announced new research demonstrating significantly lowered A1C levels with its virtual cardiometabolic program.

The research highlighted use of the program in low-income Medicare Advantage members. Significantly lowered A1C levels even occurred in areas with limited income and food access.

Vida Health’s study compared its members living in areas of low income and low access to food with members living elsewhere. The study classified such low-income areas using the USDA’s Food Access Research Atlas.

Results demonstrated that, irrespective of socioeconomic barriers, Vida interventions led to an average A1C reduction of -1.38 points. This occurred in individuals with a baseline A1C level greater than or equal to 9. The company said this underscores its program’s effectiveness in delivering equitable care.

“Diabetes is a complex disease that is heavily influenced by social determinants of health,” said Dr. Richard Frank, chief medical officer for Vida Health. “Nearly half of Americans struggle to pay for basic necessities like housing and food. At Vida, we understand that healthy living can be challenging, with many aspects out of the individual’s control. We’re committed to providing the highest quality services and resources to help promote nutritional health for anyone, regardless of where they are on their personal health journey, or what type of access they have.”

Vida’s intervention included remote sessions with Registered Dietitians and Certified Diabetes Care and Education Specialists. It also offered content related to goal-setting to account for social determinants of health (SDOH).

The company said its findings suggest the ability to deliver equitable care across SDOH barriers. Vida also said interventions that target SDOH as part of diabetes management can offer effectiveness in improving glycemic control in this population.

Earlier this year, Vida shared results from 1,128 participants in its program, with data demonstrating dramatic improvements in glycemic control.

Filed Under: Clinical Trials, Diabetes, Featured, Patient Monitoring, Technology Tagged With: ADA 2023, American Diabetes Association, Vida Health

IN CASE YOU MISSED IT

  • BD’s IV catheters plant in Utah marks 70 years
  • Novo taps Nanexa for long-acting obesity injectables with €1.17B pact
  • Abbott partners with Berry Street to add nutrition coaching to Lingo
  • Dexcom CFO to expand into COO role
  • Beta Bionics insulin patch pump scores FDA clearance

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS